Journal Article

Recapitulating thyroid cancer histotypes through engineering embryonic stem cells

Giuffrida, Dario, Pillitteri, Irene, Colarossi, Lorenzo, Sciacca, Elisabetta, Belfiore, Antonino, Verona, Francesco, Colarossi, Cristina, Stassi, Giorgio, Vella, Veronica, Bongiorno, Maria Rita, Todaro, Matilde, Modica, Chiara, Memeo, Lorenzo, Vigneri, Paolo, Turdo, Alice, Di Bella, Sebastiano, Bianca, Paola, Veschi, Veronica, Tirrò, Elena, Pistone, Giuseppe, Gaggianesi, Miriam, Porcelli, Gaetana, Mangiapane, Laura Rosa, Iacono, Melania Lo, Rizzo, Aroldo, Di Franco, Simone, Pantina, Vincenzo Davide

2023

Overview

Thyroid carcinoma (TC) is the most common malignancy of endocrine organs. The cell subpopulation in the lineage hierarchy that serves as cell of origin for the different TC histotypes is unknown. Human embryonic stem cells (hESCs) with appropriate in vitro stimulation undergo sequential differentiation into thyroid progenitor cells (TPCs-day 22), which maturate into thyrocytes (day 30). Here, we create follicular cell-derived TCs of all the different histotypes based on specific genomic alterations delivered by CRISPR-Cas9 in hESC-derived TPCs. Specifically, TPCs harboring BRAF V600E or NRAS Q61R mutations generate papillary or follicular TC, respectively, whereas addition of TP53 R248Q generate undifferentiated TCs. Of note, TCs arise by engineering TPCs, whereas mature thyrocytes have a very limited tumorigenic capacity. The same mutations result in teratocarcinomas when delivered in early differentiating hESCs. Tissue Inhibitor of Metalloproteinase 1 (TIMP1)/Matrix metallopeptidase 9 (MMP9)/Cluster of differentiation 44 (CD44) ternary complex, in cooperation with Kisspeptin receptor (KISS1R), is involved in TC initiation and progression. Increasing radioiodine uptake, KISS1R and TIMP1 targeting may represent a therapeutic adjuvant option for undifferentiated TCs. Thyroid carcinoma (TC) is the most common malignancy of endocrine organs. Here, the authors show the ability of human embryonic stem cells (hESCs) to recapitulate the different TC histotypes upon specific genomic alterations delivered by CRISPR-Cas9 and identify KISS1R and TIMP1 targeting as a therapeutic adjuvant option for undifferentiated TCs.

• Publisher: Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
• Subject: 13/1 / 13/100 / 13/106 / 13/31 / 13/51 / 38 / 38/109 / 38/22 / 38/23 / 38/77 / 38/90 / 38/91 / 631/532/71 / 64/60 / 692/4028/67/1459/1843 / 82/80 / Cancer / CD44 antigen / Cell differentiation / Cooperativity / CRISPR / Embryo cells / Embryonic Stem Cells / Gelatinase B / Genomics / Human performance / Humanities and Social Sciences / Humans / Iodine 131 / Iodine Radioisotopes / Kiss1 protein / Malignancy / Matrix metalloproteinases / Metalloproteinase / multidisciplinary / Mutation / Organs / Progenitor cells / Proto-Oncogene Proteins B-raf - genetics / Receptors, Kisspeptin-1 - genetics / Science / Science (multidisciplinary) / Stem cells / Thyrocytes / Thyroid / Thyroid cancer / Thyroid carcinoma / Thyroid Neoplasms - genetics / Tissue inhibitor of metalloproteinase 1 / Tissue Inhibitor of Metalloproteinase-1 - genetics